Crossmark

Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States

Published Online: 2021-07-22

Published Print: 2022-02

Authors

Jiang, Yiling http://orcid.org/0000-0002-1236-7550
Sarpong, Eric M.

Sears, Pamela

Obi, Engels N.
Funding

Funding for this research was provided by:

Merck Sharp and Dohme
License Information

Text and Data Mining valid from 2021-07-22

Version of Record valid from 2021-07-22
More Information

Article History

Received: 1 October 2020

Accepted: 10 June 2021

First Online: 22 July 2021

Change Date: 16 January 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40121-021-00583-8

Updates are available Correction dated 2022-01-16